Table 4.
Summary of Second-Line Treatment
| Second-Line Treatment | R-Maintenance (n=130) | Observation (n=189) |
|---|---|---|
| Second-line treatment, no. (%) | ||
| R-monotherapy | 47 (36) | 78 (41) |
| R-chemotherapy | 40 (31) | 57 (30) |
| Chemotherapy | 13 (10) | 7 (4) |
| Investigational therapy | 9 (7) | 14 (7) |
| Radiotherapy | 5 (4) | 18 (10) |
| Radioimmunotherapy | 8 (6) | 9 (5) |
| Bone marrow transplant | 1 (1) | 0 (0) |
| CM: radiotherapy | 1 (1) | 1 (<1) |
| CM: radioimmunotherapy | 1 (1) | 2 (1) |
| CM: bone marrow transplant | 3 (2) | 2 (1) |
| Other | 2 (2) | 1 (<1) |
| Reason to start second-line treatment | ||
| PD | 125 (96) | 173 (92) |
| Maintain a response | 1 (1) | 2 (1) |
| Other | 4 (3) | 14 (7) |
| Best response to second-line treatment | ||
| CR/PR | 72 (61) | 100 (57) |
| SD | 23 (19) | 31 (18) |
| PD | 23 (19) | 44 (25) |
Abbreviations: CM, combined modality; CR, complete response; PD, progressive disease; PR, partial response; R-chemotherapy, rituximab plus chemotherapy; R-maintenance, rituximab maintenance; R-monotherapy, rituximab monotherapy; SD, stable disease.